Globally, breast cancer represents 1 in 8 cancer diagnoses, with over 2.3 million new cases in 2020 alone, as reported by the World Health Organization. In this complex landscape, the challenge remains in effectively identifying responders to specific treatments, hindered by the absence of comprehensive preclinical models that accurately mirror the tumor-immune micro-environment (TME).

Our pioneering development introduces the first-ever high-throughput, vascularized, immunocompetent breast tumoroid model. Utilizing an innovative micro physiological system (MPS) and microfabrication techniques, we’ve achieved a groundbreaking feat in cellular modeling. This model, cultured in a standard multiwell plate, allows for the cultivation of up to 91 tumoroids per well, achieving full vascularization and immune competence within 48 hours.

This poster, detailing our revolutionary approach and showcase results, offers a glimpse into the future of precision oncology. It highlights how our methodology paves the way for developing patient-specific, tumor-derived models, crucial for predicting individual drug responses.

The poster, title: A high throughput vascularized immunocompetent tumoroid model in standard multiwell plates for precision oncology – is free to download here. Don’t miss out!